-
Dactolisib (codenamed NVP-BEZ235 and BEZ-235, also
known as RTB101) is an
imidazoquinoline derivative acting as a PI3K inhibitor. It also
inhibits mTOR...
-
clinical trial published in 2018
showed that
everolimus in
combination with
dactolisib decreased the rate of
reported infections in an
elderly po****tion. Compared...
-
derivatives and
compounds are
often used for
antiviral and
antiallergic creams.
Dactolisib Imiquimod Gardiquimod Resiquimod Sumanirole Hemmi, H; Kaisho, T; Takeuchi...
-
repair capacity of HLS. Also
blocking both HR and NHEJ
repair pathways by
dactolisib (NVP-BEZ235)
inhibitor showed that
repair of HLS is not
dependent on HR...
-
phosphorylation of AKT Ser473 residue. Dual mTOR/PI3K
inhibitors include dactolisib, voxtalisib, BGT226, SF1126, PKI-587 and many more. For example, Novartis...
- Parkinson's disease.
After a short-term
treatment with the mTOR
inhibitors dactolisib and everolimus, in
elderly (65 and older),
treated subjects had a reduced...
- 1–3
previous lines of therapy.
Results are
expected for
February 2023.
Dactolisib (codenamed BEZ235, NVP-BEZ235; dual pan-class I PI3K and mTOR inhibitor)...
- 5-c]quinolin-2-one scaffold. The
first important representative is the
inhibitor is
Dactolisib (NVP-BEZ235),
which was
first published by
Novartis as a
selective mTOR/PI3K...
-
Umirolimus Zotarolimus; ATP-competitive / indirect:
Berberine Cur****in
Dactolisib EF-24
Epigallocatechin gallate HY-124798 NV-5440
Pterostilbene Quercetin...
